A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.
about
The management of glaucoma and intraocular hypertension: current approaches and recent advancesMeta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertensionThe effect on intraocular pressure of latanoprost once or four times dailyEffects of latanoprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeabilityGlaucoma medical treatment: philosophy, principles and practice.The outcome of mitomycin C trabeculectomy and laser suture lysis depends on postoperative management.Use of latanoprost to reduce acute intraocular pressure rise following neodymium: Yag laser iridotomy.Latanoprost versus combined therapy with timolol plus dorzolamide: IOP-lowering effect in open-angle glaucoma.Performing meta-analysis with incomplete statistical information in clinical trialsRecent advances in pharmacotherapy of glaucomaFirst-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressureMeta-analysis of randomized controlled trials comparing latanoprost with timolol in the treatment of Asian populations with chronic angle-closure glaucomaIncidence, severity and factors related to drug-induced keratoepitheliopathy with glaucoma medications.Ocular lubricant use in medically and surgically treated glaucoma: a retrospective longitudinal analysis.Efficacy of Garcinia kola 0.5% Aqueous Eye Drops in Patients with Primary Open-Angle Glaucoma or Ocular HypertensionComparative efficacy and safety of the fixed versus unfixed combination of latanoprost and timolol in Chinese patients with open-angle glaucoma or ocular hypertension.Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertensionTherapeutic potential of prostaglandin analogues in glaucoma.Bimatoprost: a member of a new class of agents, the prostamides, for glaucoma management.A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprostThe impact of intraocular pressure reduction on retinal ganglion cell function measured using pattern electroretinogram in eyes receiving latanoprost 0.005% versus placebo.Clinical options for the reduction of elevated intraocular pressureComparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension.A double masked comparison of the intraocular pressure reducing effect of latanoprost 0.005% and 0.001% administered once daily in open angle glaucoma and ocular hypertension.Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists. French Latanoprost Study Group, and the Swedish LaA comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomised study. Ireland Latanoprost Study Group.Emerging drugs for ophthalmic diseases.Additive effect of unoprostone and latanoprost in patients with elevated intraocular pressure.Incidence of iris colour change in latanoprost treated eyes.Unoprostone as adjunctive therapy to timolol: a double masked randomised study versus brimonidine and dorzolamideA 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertensionShort term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies.Patterns of opioid analgesic prescription among patients with osteoarthritis.Intraocular pressure after replacement of current dual therapy with latanoprost monotherapy in patients with open angle glaucoma.Bimatoprost versus latanoprost in lowering intraocular pressure in glaucoma and ocular hypertension: results from parallel-group comparison trials.Current and emerging medical therapies for glaucoma.Glaucoma medications: use and safety in the elderly population.The side effects of the prostaglandin analogues.The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients. A randomized, double-masked comparison with timolol 0.5%.Predictive value of the efficacy of glaucoma medications in regulatory trials: Phase I-III to post-marketing studies.
P2860
Q22305849-79785D04-DDF3-46C6-A4EA-590B7C2C6CA2Q24672885-EC53BD47-27A7-4ACC-9A9F-B469AAE0034FQ28360261-77FB5D8B-5FD6-478D-83C1-A3745E7D607DQ28379588-02E25615-4D54-43D2-8869-C9A3AD7CD188Q30327343-DD0C9B2F-3DF3-4DA7-83EB-A879A18AE570Q30827359-6834ED4D-5D69-4239-8AEF-4D7991EE409BQ31075828-964F0D35-12F6-4148-9897-712A516099AEQ31890726-9F2D5B9E-1C0E-448A-AD07-626D6696F322Q33360471-74AA36C6-293C-4CE3-B05A-7B5C60D66AAFQ33521178-1DEE4A8A-B914-4726-AFB2-115F68AF3696Q33534044-DB8945CC-188D-44AC-8FF6-43923D9AF5B5Q33590856-CA86666C-0141-45E6-9841-BAF604AED339Q33819802-F52BD064-FA0F-4F44-B71D-7F3C18B6EB9FQ33865232-4A8BE5C1-F0DD-4314-9467-7B52BB9A0381Q33892713-932FEA8C-BC3E-44D8-84AC-026042A4F17AQ33996251-6CF82720-8C73-406A-A891-11B5F8BA82A1Q34043309-08E999D6-B0D0-4A98-8D1A-7DDDB050D32BQ34204357-9C754393-C584-41C0-BB58-558FF3D68868Q34204376-65DE1F81-040C-452F-B05B-E8EEFC54CF7EQ34399842-EDC40ED1-E5FA-4208-B860-21D112B5D342Q34511054-155D1392-999D-4439-B8C7-4A586EAAB1B0Q34708267-01F61C5F-3FBA-4B0C-8AA8-8083D7F97C4DQ35237431-279B4D06-70AA-4B33-990D-BBF7C71623B3Q35298399-6F8AF7A5-205B-42FC-AFBE-DC09CE1066D2Q35313371-321DF8A8-133C-4FCC-911C-114704971F25Q35314724-B2442A4C-D56E-4373-AA55-9D022A1BB35AQ35581180-80E4A4AD-9166-4E70-A310-EAD1A003E912Q35589367-AE3A766B-3DEF-49AB-A103-EDD6F94318F5Q35590132-A50A107B-85F8-4153-BCC9-8C0E588D1A8CQ35590963-9ED970AC-ADFD-4A92-8F5F-70F08CA19CE1Q35591747-4B813FE8-D096-4592-817D-C1D2259B0F95Q35592524-E39DC610-0860-4D56-BA5C-4BFB2D167D12Q35775628-093DDA26-E14E-4DB0-80E4-79F767B02B9DQ35894656-4882F518-9E44-467F-822D-41035A62855AQ35987460-BF3319E4-7972-494A-814A-74489B1859A5Q36066033-906C2F2E-9C0D-47E9-96AE-8AB34205AF04Q36491778-18CF11E6-F973-498F-98DF-14BD4963ADB3Q36689066-1903083A-C25B-40C2-8A28-72C4A7A08D11Q36846752-702DD00F-8696-4201-B050-557EA1A6F3A8Q36856440-0E791725-1B96-4316-A69E-609869F20524
P2860
A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
A six-month, randomized, doubl ...... . The Latanoprost Study Group.
@en
A six-month, randomized, doubl ...... . The Latanoprost Study Group.
@nl
type
label
A six-month, randomized, doubl ...... . The Latanoprost Study Group.
@en
A six-month, randomized, doubl ...... . The Latanoprost Study Group.
@nl
prefLabel
A six-month, randomized, doubl ...... . The Latanoprost Study Group.
@en
A six-month, randomized, doubl ...... . The Latanoprost Study Group.
@nl
P1433
P1476
A six-month, randomized, doubl ...... . The Latanoprost Study Group.
@en
P2093
Stjernschantz J
P304
P356
10.1016/S0161-6420(96)30750-1
P577
1996-01-01T00:00:00Z